Pharyngeal Carcinoma — Trials

Pharyngeal Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

994 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 357
Recruiting: 191
Ph III recruiting: 58
Growth YoY: +6.7%
Industry share: 8%
Top sponsor: Sun Yat-sen University
Termination share: 31.7%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (85)

clinicaltrialsPublishedShowing 1–50 of 106 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06589804	Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment	recruiting	Phase 3	158	National Cancer Institute (NCI)NIH	1	Sep 29, 2026	clinicaltrials
NCT06629597	A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma (TAISHAN-301)	active not recruiting	Phase 3	400	MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY	1	Sep 17, 2026